Moderna stock falls 5.65 percent as Nasdaq-100 entry nears

Published on 10/06/2026 at 17:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock was set for Nasdaq-100 inclusion on October 9, 2026, while second-quarter revenue reached USD 145 million. The stock traded at USD 191.73 on October 6.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna stock was trading at USD 191.73 on Nasdaq on October 6, 2026, down 5.65 percent at 11:03 a.m. ET. The move came as the biotechnology company approaches its Nasdaq-100 entry on October 9, while investors weigh a still-loss-making business against a rapidly advancing oncology pipeline.

Nasdaq entry arrives October 9

According to Nasdaq on October 1, 2026, Moderna will become a Nasdaq-100 component before the market opens on October 9, replacing Warner Bros. Discovery. The index change gives Moderna a scheduled market-structure catalyst, but it does not alter the company's revenue or earnings profile.

That distinction matters because Moderna's latest reported quarter remained financially difficult. In the second-quarter 2026 earnings call, Yahoo Finance carried management's report of USD 145 million in revenue, up 2 percent from USD 142 million a year earlier. The GAAP net loss narrowed to USD 782 million from USD 825 million, while loss per share improved to USD 1.97 from USD 2.13.

Revenue growth meets pipeline risk

Management reiterated a 2026 revenue-growth outlook of up to 10 percent during the July 31, 2026, earnings call. The same call also described cash and investments of USD 6.9 billion at the end of the second quarter and a lower projected 2026 cash-cost framework of USD 4.0 billion.

The next major operating checkpoint is oncology. Moderna said on September 21, 2026, that Phase 3 data for intismeran autogene in resected stage IIB-IV melanoma would be presented at a Presidential Symposium on October 24. The company is developing the individualized mRNA therapy with Merck and will also host an investor webcast that date.

Valuation remains the counterweight to the pipeline narrative. As Yahoo Finance reported on September 30, 2026, Citi downgraded Moderna to Sell from Hold while raising its price target from USD 60 to USD 80. The higher target still sat below the stock's recent trading level, underscoring how heavily the current valuation depends on clinical execution.

Stock remains below its yearly high

Moderna's October 6, 2026, trading range was USD 187.69 to USD 212.19, with volume at 10,651,174 shares. The USD 191.73 price stood 9.64 percent below the 52-week high of USD 212.19 and left the company with a market capitalization of USD 76.1 billion.